Silk Road Medical Acquired by Boston Scientific

For an equity amount of around $1.26 billion, Boston Scientific is going to purchase Silk Road Medical, a manufacturer of tools that avoid strokes.

The only publicly accessible equipment to be utilised during transcarotid artery revascularization (TCAR), a minimally invasive treatment intended for assisting people who have carotid artery disease, are those made accessible by Silk Road.

The FDA authorised Silk Road’s TCAR system in 2015 with the goal of lowering the likelihood of stroke and the difficulties that come with open surgery.

Boston Scientific can leverage its natural assets to introduce fresh products, grow into emerging markets such as China and Japan, and enhance TCAR acceptance in the U.S. market, according to BTIG analyst Marie Thibault.

Cat Jennings, president of vascular, peripheral interventions, at Boston Scientific, stated: “The addition of this clinically differentiated technology to our vascular portfolio demonstrates our continued commitment to provide meaningful innovation for physicians who care for patients with peripheral vascular disease.”